We are live on ! Find out more
RCP

Remedium Capital Partners Portfolio holdings

AUM $452M
This Fund
S&P 500
This Quarter Est. Return
+85.68%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$170M
AUM Growth
–
Cap. Flow
+$143M
Cap. Flow %
84.17%
Top 10 Hldgs %
100%
Holding
6
New
6
Increased
–
Reduced
–
Closed
–
Avg Time Held
0 quarters
Top 10 Avg Time Held
0 quarters
Top 20 Avg Time Held
0 quarters

Top Buys

Rank Stock Value
1
ORKA icon
Oruka Therapeutics
ORKA
+$43.3M
2
SYRE icon
Spyre Therapeutics
SYRE
+$38.1M
3
APGE icon
Apogee Therapeutics
APGE
+$36.8M
4
JBIO icon
Jade Biosciences
JBIO
+$18.5M
5
CBIO icon
Crescent Biopharma
CBIO
+$4.6M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
SYRE icon
1
Spyre Therapeutics
SYRE
$8.03B
$47.7M 28.03%
+1,456,231
New +$38.1M
2025 Q4
0 quarters
ORKA icon
2
Oruka Therapeutics
ORKA
$5.32B
$47.1M 27.64%
+1,552,414
New +$43.3M
2025 Q4
0 quarters
APGE icon
3
DELISTED
Apogee Therapeutics
APGE
$44M 25.88%
+583,591
New +$36.8M
2025 Q4
0 quarters
JBIO icon
4
Jade Biosciences
JBIO
$890M
$24.3M 14.3%
+1,577,750
New +$18.5M
2025 Q4
0 quarters
CBIO icon
5
Crescent Biopharma
CBIO
$537M
$4.28M 2.52%
+361,250
New +$4.6M
2025 Q4
0 quarters
DMRA
6
Damora Therapeutics
DMRA
$1.25B
$2.77M 1.63%
+120,473
New +$2.09M
2025 Q4
0 quarters

Similar funds

WC
Winmill & Co Walpole, New Hampshire $452M AUM 56.84% 1-Year Est. Return
FDS
Freedom Day Solutions Houston, Texas $452M AUM 24.78% 1-Year Est. Return
IWMA
Ironwood Wealth Management (Arizona) Chandler, Arizona $451M AUM 13.94% 1-Year Est. Return
BAMG
Brand Asset Management Group Chesterfield, Missouri $452M AUM 25.97% 1-Year Est. Return
ECM
Endure Capital Management Austin, Texas $451M AUM
BFT
Bitwise Funds Trust San Francisco, California $452M AUM
LL
LPWM LLC Minneapolis, Minnesota $451M AUM 18.82% 1-Year Est. Return
CFA
CWS Financial Advisors Kalamazoo, Michigan $451M AUM 11.68% 1-Year Est. Return

Remedium Capital Partners's Q4 2025 Portfolio in Review

Q4 2025 is the first quarter with a 13F filing on record for Remedium Capital Partners, which disclosed 6 positions worth $170M. Its ten largest holdings account for 100% of the portfolio.

Its largest position is Oruka Therapeutics: 1,552,414 shares worth $47.1M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets.

  • Remedium Capital Partners's largest Q4 2025 buy was Oruka Therapeutics: 1,552,414 shares worth $47.1M.
  • Remedium Capital Partners's ten largest holdings make up 100% of its $170M portfolio in Q4 2025.
  • Remedium Capital Partners disclosed 6 positions in Q4 2025, its first 13F filing on record.

Based on Remedium Capital Partners's 13F filing for Q4 2025, filed 12 Feb 2026.